SEC 13F Intelligence

Propel Bio Management, LLC / TCRX

Propel Bio Management, LLC’s Tscan Therapeutics Inc Position

Does Propel Bio Management, LLC own Tscan Therapeutics Inc (TCRX)? Not currently — the last reported position was 1.93M shares worth $4M in Q3 2025; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$4M
Q3 2025
Shares
1.93M
% of Portfolio
+3.52%
Quarters Held
8
position exited

Position History TCRX

Reported value by quarter
Q4 ’23: $12MQ4 ’23Q1 ’24: $17MQ1 ’24Q2 ’24: $12MQ2 ’24Q3 ’24: $10MQ3 ’24Q4 ’24: $6MQ4 ’24Q1 ’25: $3MQ1 ’25Q2 ’25: $3MQ2 ’25Q3 ’25: $4MQ3 ’25filingsflow.com
QuarterSharesValue% of Portfolio
Q3 20251.93M$4M+3.52%
Q2 20252.09M$3M+3.67%
Q1 20252.09M$3M+3.35%
Q4 20242.09M$6M+6.30%
Q3 20242.09M$10M+6.03%
Q2 20242.09M$12M+7.92%
Q1 20242.09M$17M+9.65%
Q4 20232.09M$12M+10.09%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Propel Bio Management, LLC’s full portfolio or all institutional holders of TCRX.